Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kura Oncology (KURA)
NASDAQ:KURA
Kura Oncology (KURA) Stock Price & Analysis
447 Followers
KURA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$7.41 - $24.17
Previous Close$17.68
Volume1.65M
Average Volume (3M)1.42M
Market Cap
$1.35B
Enterprise Value$939.34M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)-8.5
Beta1.09
Next Earnings
May 07, 2024EPS Estimate
-$0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.08
Shares Outstanding76,136,963
10 Day Avg. Volume673,059
30 Day Avg. Volume1,418,621
Standard Deviation0.18
R-Squared0.07
Alpha0.00773
Financial Highlights & Ratios
Price to Book (P/B)3.56
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-10.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$31.09Price Target Upside75.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Kura Oncology News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressFirst ccRCC patient dosed in KO-2806 combination studies indicates progression in clinical trials.
Drug Development MilestonesKura has outlined clear upcoming milestones for its clinical programs, with several key developments expected by mid-2024.
Financial StrengthThe company has a substantial cash runway expected into 2027, indicating a strong financial position.
Bears Say
Drug EfficacyQuestions on the drug's overall activity have emerged due to lack of activity in the KMT2A-r population.
EarningsKura reported no revenue for the fourth quarter.
Stock ValuationThe stock could decline significantly if efficacy and safety concerns arise.
---
Ownership Overview
7.49% Insiders
16.02% Mutual Funds
15.29% Other Institutional Investors
61.20% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KURA FAQ
What was Kura Oncology’s price range in the past 12 months?
Kura Oncology lowest stock price was $7.41 and its highest was $24.17 in the past 12 months.
What is Kura Oncology’s market cap?
Currently, no data Available
When is Kura Oncology’s upcoming earnings report date?
Kura Oncology’s upcoming earnings report date is May 07, 2024 which is in 18 days.
How were Kura Oncology’s earnings last quarter?
Kura Oncology released its earnings results on Feb 27, 2024. The company reported -$0.55 earnings per share for the quarter, beating the consensus estimate of -$0.551 by $0.001.
Is Kura Oncology overvalued?
According to Wall Street analysts Kura Oncology’s price is currently Undervalued.
Does Kura Oncology pay dividends?
Kura Oncology does not currently pay dividends.
What is Kura Oncology’s EPS estimate?
Kura Oncology’s EPS estimate is -$0.55.
How many shares outstanding does Kura Oncology have?
Kura Oncology has 76,136,960 shares outstanding.
What happened to Kura Oncology’s price movement after its last earnings report?
Kura Oncology reported an EPS of -$0.55 in its last earnings report, beating expectations of -$0.551. Following the earnings report the stock price went down -1.746%.
Which hedge fund is a major shareholder of Kura Oncology?
Among the largest hedge funds holding Kura Oncology’s share is Deerfield Management Company, LP. It holds Kura Oncology’s shares valued at 76M.
---
Kura Oncology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.09 (75.85% Upside)
$31.09 (75.85% Upside)
Blogger Sentiment
Bullish
KURA Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 917.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $205.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.9%
Last 30 Days ▼ 13.9%
Last 30 Days ▼ 13.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
56.29%
12-Months-Change
Fundamentals
Return on Equity
-37.34%
Trailing 12-Months
Asset Growth
-1.62%
Trailing 12-Months
Company Description
Kura Oncology
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA.
---
KURA Company Deck
---
KURA Earnings Call
Q4 2024
0:00 / 0:00
---
KURA Stock 12 Months Forecast
Average Price Target
$31.09
▲(75.85% Upside)
Technical Analysis
Best Analysts Covering KURA
1 Year
1 Year Success Rate
10/14 ratings generated profit
1 Year Average Return
+44.01%
reiterated a buy rating last month
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +44.01% per trade.
---